Endocrine Abstracts

Hypoparathyroidism is a rare disorder characterised by hypocalcaemia and hyperphosphataemia in the presence of low or inappropriately normal parathyroid hormone levels. Currently there are limited data on the burden of illness and healthcare resource utilisation (HCRU) associated with chronic hypoparathyroidism in Canada. A retrospective cohort analysis with matched controls was conducted to examine HCRU in patients with chronic hypoparathyroidism in Ontario, Canada. Data were...

Objective: The purpose of this study was to evaluate the psychometric properties of a novel, patient-reported outcome (PRO) measure, the Hypoparathyroidism (HPT) Symptom Diary (HPT-SD), using data collected during a cross-sectional, noninterventional, observational study. The HPT-SD, developed according to the US Food and Drug Administration PRO guidance, addresses the severity of key symptoms (muscle cramping, tingling and muscle spasms/twitching, fatigue, cognition, emotions...

Chronic hypoparathyroidism (HypoPT) is a rare disease associated with a variety of symptoms and diminished health-related quality of life (HRQoL). This study aimed to characterise and quantify the symptom burden, HRQoL, and overall disease impact in patients receiving recombinant human parathyroid hormone (rhPTH1-84, Natpar®) for inadequately controlled HypoPT and in symptomatic patients receiving standard therapy (ST; calcium and/or vitamin D supplements). A w...

Background: Prior small studies have suggested increased risk of infections in patients with hypoparathyroidism (HypoPT). This study using a large managed care cohort evaluated whether chronic HypoPT is associated with increased risk of sepsis, respiratory infections, and kidney or other genitourinary (GU) infections.Methods: A retrospective cohort study using a US commercial claims database (Q1 2007–Q2 2017) was conducted to examine the association...

Background: Little is known about the risk of developing nephrolithiasis and nephrocalcinosis in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). This study evaluated whether HypoPT is associated with increased risk of these conditions.Methods: This retrospective cohort study, based on a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of nephrolithiasis a...

Background: Previous studies of smaller size signaled heightened risk of CKD in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). However, little is known about CKD progression, including progression to end-stage kidney disease (ESKD), in HypoPT patients.Methods: A retrospective cohort study, using a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of CKD b...

Background: Among chronic hypoparathyroidism (HypoPT) patients, the baseline prevalence of type 2 diabetes (T2D) appeared to be higher than the general population in previous studies. Since little is known about the potential assocation between HypoPT and T2D, this study evaluated whether HypoPT is associated with increased risk of T2D.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 – Q2 2017), was conducted ...

Significant knowledge gaps exist regarding the humanistic effects of hypoparathyroidism, a rare, debilitating disorder. We report results from a global survey to characterise the burden of hypoparathyroidism from the patient perspective. An anonymous survey was conducted in patients with uncontrolled chronic hypoparathyroidism (as determined by patients’ report of persistent symptoms and/or poorly controlled calcium levels as told by their physician) despite receiving con...

Background: Prior small studies have suggested increased risk of cardiovascular (CV) conditions in patients with hypoparathyroidism (HypoPT). We evaluated whether chronic HypoPT is associated with increased risk of select CV hard endpoints (i.e., myocardial infarction (MI), stroke, and a composite CV endpoint) in a large contemporary cohort.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 - Q2 2017), was conducted ...

Although chronic hypoparathyroidism is known to negatively affect health-related quality of life (HRQoL), burden of illness is less well defined in patients whose disease is not adequately controlled on conventional therapy. We report burden of illness for the European subset of a patient survey in 13 countries globally. 398 adults with chronic hypoparathyroidism not adequately controlled on conventional therapy (recruited by treating physician or patient association) complete...